Blincyto (blinatumomab) / Astellas, Amgen 
Welcome,         Profile    Billing    Logout  
 29 Diseases   78 Trials   78 Trials   3560 News 


«12...678910111213141516...4445»
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal, IO biomarker:  PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. (Pubmed Central) -  Dec 16, 2022   
    We described a PAX5-driven enhancer at the CD58 locus, which was disrupted by PAX5 P80R, and the loss of CD58 abolished blinatumomab-induced T cell activation with global changes in transcriptomic/epigenomic program. In conclusion, we identified previously unidentified genetic mechanisms of blinatumomab resistance in B-ALL, suggesting strategies for genomics-guided treatment individualization.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal, Residual disease, IO biomarker:  Measurable residual disease in acute lymphoblastic leukemia: How low is low enough? (Pubmed Central) -  Dec 16, 2022   
    Emerging data suggest these higher sensitivity methods are superior for identifying patients at lowest risk for relapse, but it remains controversial whether to institute therapies such as blinatumomab or chimeric antigen receptor (CAR)-T cells or move patients to allogeneic hematopoietic cell transplant (alloHCT) when they have quantifiable disease burden less than 10. With additional evidence to facilitate integration of highly sensitive MRD quantification into clinical care and to contextualize MRD within the genotype of individual patients, it will likely be increasingly possible to identify patients able to avoid alloHCT and potentially even de-escalate therapy.
  • ||||||||||  obecabtagene autoleucel (AUTO1) / Autolus
    Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR, in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia and Factors Associated with Durable Response. () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_906;    
    P1
    METHODS Subjects ≥ 16y received fludarabine (30mg/m 2 x3) and cyclophosphamide (60mg/kg x1) followed by split dose AUTO1 (day 0: ≥20% Bone Marrow (BM) blasts, AUTO1 dose=10 x10 6 ; <20% BM blasts, AUTO1 dose=100 x10 6...RESULTS 20 adult B-ALL patients (median age, 41.5y), previously treated with blinatumomab (25%), inotuzumab ozogamicin (50%) and allogeneic stem cell transplantation (65%), were infused with AUTO1...This suggests that CAR-T persistence and B cell aplasia (denoting functional persistence) are associated with long-term clinical responses. We will present further analysis of factors associated with response and relapse at the conference.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Clinical Practice Patterns and Factors Driving Usage of Consolidative Stem Cell Transplantation Post-Tisagenlecleucel () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_895;    
    In this survey of 22 tisagenlecleucel-prescribers, over half of respondents indicated that the decision to recommend cHSCT post-tisagenlecleucel was patient-dependent. Increased disease burden pre-infusion, extramedullary disease, KMT2Ar, and history of treatment-refractoriness were associated with increased likelihood of recommending cHSCT, while having a history of HSCT, not being a TBI candidate, and Trisomy 21 were associated with decreased likelihood of recommending cHSCT.
  • ||||||||||  cyclophosphamide / Generic mfg.
    Anaphylaxis to Cyclophosphamide Metabolites during Lymphodepletion for CAR-T Therapy () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_819;    
    Case description: A 13 year old boy was diagnosed with very high risk ALL in 2015 and had 2 isolated CNS relapses treated with intensified chemotherapy (chemo) and cranial radiation (1 st relapse) and Blinatumomab with intrathecal (IT) chemo followed by sibling donor HSCT (2 nd relapse)...Later, during lymphodepletion with fludarabine (Flu) and Cy, physiologic replacement hydrocortisone (HC) was briefly held to prevent interference with CAR-T function...CAR-T infusion was subsequently delayed by skin GVHD requiring glucocorticoids and COVID-19 infection treated with convalescent plasma and nirmatrelvir/ritonavir...Onset of anaphylaxis within hours rather than minutes after Cy administration supports hypersensitivity to Cy metabolites rather than to the drug itself. This case highlights the importance of consideration of sensitivity to Cy metabolites as well as acquired donor-specific allergy even when alternative explanations are likely.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Phase I Trial of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder for Adults with Relapsed/Refractory B-ALL () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_725;    
    P1
    Pts were treated with cyclophosphamide 300 mg/m 2 /d and fludarabine 30 mg/m 2 /d for 3 days followed by infusion of JCAR021 for R/R B-cell malignancies (NCT03103971) on 1 of 2 cohorts: high marrow burden ALL (HMB; > 5% bone marrow [BM] blasts; n=12); low marrow burden ALL (LMB; ≤ 5% BM; n=11)...Thirteen (57%) had received blinatumomab; 12 (52%) had received inotuzumab ozogamicin...CD19 CAR T cells with a fully human scFv for R/R adult B-ALL led to high rates of MRD-negative marrow and EM responses, but durable responses in the absence of consolidative allo-HCT were only observed in 3 pts. Additional strategies are needed to improve CAR T-cell persistence and outcomes of CD19 CAR T-cell therapy for adult R/R B-ALL.